Matt Hoffman, Associate Editorial Director for NeurologyLive®, has covered medical news for MJH Life Sciences, NeurologyLive®’s parent company, since 2017. He hosts the NeurologyLive® Mind Moments® podcast, as well as the Medical World News show, Deep Dive. Follow him on Twitter @byMattHoffman or email him at email@example.com
Episode 76: ECTRIMS 2022 and the Latest in MS AdvancesNovember 4th 2022
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Darin Okuda, MD; Federica Picariello, PhD; Brenda Banwell, MD; Riley Bove, MD; Tomas Kalincik, MD, PhD; and Marisa McGinley, DO. [LISTEN TIME: 34 minutes]
Palatability Strategies Show Promise for Addressing AMX0035 Taste Concerns Among Patients With ALSNovember 2nd 2022
As patients with ALS may have altered taste perception and have expressed that bitterness is associated with AMX0035 (Relyvrio; Amylyx) administration, a number of coping strategies have suggested a workaround to ensure treatment adherence and effectiveness.
Nondisabling MS Relapses Associated With Higher Disability AccumulationOctober 28th 2022
In a late-breaking presentation in ECTRIMS, data from the MSBase international registry was suggestive of higher disability accumulation risk compared with those who did not experience relapse, in both treated and untreated patients with MS.
Third BNT162b2 COVID-19 Vaccine Dose Revives Humoral Response in MS Among Those Treated With Ocrelizumab, FingolimodOctober 28th 2022
After preliminary data suggested that humoral response may be delayed among those vaccinated against COVID-19 treated with ocrelizumab, new data from the ECTRIMS Congress suggest a third booster dose can revive such response safely.
Cladribine Shows Efficacy, Tolerability Among Patients With MS Switching From Infusion DMTsOctober 26th 2022
In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), natalizumab (Tysabri; Biogen), and alemtuzumab (Lemtrada; Sanofi Genzyme).
NeurologyLive® Brain Games: October 23, 2022October 23rd 2022
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.
Supernus Issued CRL for Continuous Apomorphine Infusion in Parkinson DiseaseOctober 10th 2022
The NDA for the Supernus therapy, supported by data from the phase 3 TOLEDO study in patients with Parkinson disease, will require additional information and 6 months of further review. No additional efficacy or safety studies are required.
NeurologyLive® Top Expert Interviews: September 2022October 6th 2022
Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.
NeurologyLive® Brain Games: October 2, 2022October 2nd 2022
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology, related to the recent 4th Annual International Congress on the Future of Neurology®.
Aerobic Exercise for MS Positively Affects Motor-related Tract and Nuclei Microstructural IntegritySeptember 28th 2022
Although data from the EMSES study failed to reveal a reduction in relapse rates or global brain atrophy, half of the important motor-related tracts and nuclei observed displayed higher structural integrity in exercise patients.
Alzheimer Disease Agent Lecanemab Shows Reduction in CDR-Sum of Boxes in Clarity ADSeptember 28th 2022
The investigational treatment from Eisai and Biogen significantly reduced the Clinical Dementia Rating-Sum of Boxes scores among patients with early AD, with safety and ARIA-E and ARIA-H incidence as expected.
NeurologyLive® Brain Games: September 25, 2022September 25th 2022
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.
MS Treatment Glatiramer Acetate Depot Injection Proves Positive in Topline Phase 3 DataSeptember 21st 2022
The Mapi Pharma treatment, administered intramuscularly at 40 mg, reduced annualized relapse rates among a population of patients with relapsing multiple sclerosis. Secondary outcomes are still being analyzed.
WHO’s 6 Action Steps to Address Parkinson Disease Disparities GloballySeptember 18th 2022
Nicoline Schiess, MD, MPH, and colleagues offer insight into the recent publication of the World Health Organization’s 6 action steps aimed at addressing global disparities in individuals with Parkinson disease.
Rituximab Displays Superiority to Azathioprine, Mycophenolate Mofetil as Initial NMOSD TreatmentSeptember 13th 2022
Among a cohort of more than 300 patients in China, those with APQ4 positive NMOSD reported a significantly lower risk of relapse among those treated with rituximab compared with the other groups.